Our
mission : optimize patient care
by providing innovative treatments
Gercor concentrates its efforts
on only one mission : clinical research
Gercor's doctors treat their patients with the latest treatments using
new therapeutic weapons, paying attention to their efficiency and their
tolerance.
Gercor's first priority is immediate
therapautic benefit for patients :
The goal of so-called phase II treatments is to prove the therapeutic
effectiveness, to evaluate the effectiveness/safety, and to examine
undesirable side effects.
The goal of so-called phase III treatments is to demonstrate the superiority
of a treatment that has come out of phase II over the standard treatment
of the cancer concerned.
Gercor is open to any initiative for an innovative therapeutic study
Any proposal for a new treatment made by any member doctor is assessed
and then selected by the Scientific Council* by consensus and based
on three criteria:
how relevant it is
how feasible it is
how realistic it is
Thanks to its network, Gercor
offers patients
easy access to its up-to-date treatments
To achieve this goal, Gercor :
stimulates the inclusion into its network of the greatest number
of physicians involved in the treatments it is conducting,
offers vital logistical assistance to research physicians whose
job is to direct and monitor the application of the treatments to
patients.
Such help includes :
information transmission,
the drafting of administrative and financial requirements to do
with each therapeutic trial,
the management of inclusion and randomization of patients for each
trial,
filling in each patient's data in the observation notebooks by
our clinical research technicians,
filling each patient's data in the data base,
organizing information sessions for each scientific committee,
presenting the results for publications or presentations at international
congresses.